Skip to content

Drug interactions

Aprepitant + Lorlatinib

Severity: Moderate

Aprepitant and Lorlatinib: moderate interaction.

Last updated

For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.

Summary

Lorlatinib induces CYP3A4 and may lower aprepitant concentrations, potentially reducing antiemetic protection. Aprepitant, a CYP3A4 substrate, may also modestly affect lorlatinib. Lorlatinib labeling warns against combining it with sensitive CYP3A substrates.

What this interaction means in plain words

Aprepitant and Lorlatinib can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.

Aprepitant belongs to Gastrointestinal Tract; Lorlatinib belongs to Oncology.

Evidence level: Moderate

Why it happens

Lorlatinib induces CYP3A4, increasing aprepitant clearance.

What to do

Monitor for breakthrough nausea and vomiting and add other antiemetics if needed; consider a non-CYP3A4-dependent antiemetic strategy.

What to ask your pharmacist

  • Should I take them at different times of day?
  • Does the dose of either medicine need to change?
  • Is there anything I should avoid, such as alcohol or certain foods, while on both?

Bring a full list of your medicines, including over-the-counter products, supplements and herbal remedies, to every pharmacy visit.

Pro+ members

Unlock the full page

Create an account and start a Pro+ trial to unlock the full management advice for Aprepitant and Lorlatinib, the additional notes, the evidence detail and the whole-prescription interaction checker.

  • Full clinical management advice
  • Additional notes
  • Evidence detail
  • Interaction checker for a whole prescription

Try Pro+ free for 7 days on the web. No card needed.

Frequently asked questions

Can I take Aprepitant with Lorlatinib?

MediHelp rates the interaction as moderate. Aprepitant and Lorlatinib can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Lorlatinib induces CYP3A4 and may lower aprepitant concentrations, potentially reducing antiemetic protection. Aprepitant, a CYP3A4 substrate, may also modestly affect lorlatinib. Lorlatinib labeling warns against combining it with sensitive CYP3A substrates.

How serious is the interaction between Aprepitant and Lorlatinib?

MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor for breakthrough nausea and vomiting and add other antiemetics if needed; consider a non-CYP3A4-dependent antiemetic strategy.

What other medicines interact with Aprepitant?

MediHelp also lists interactions of Aprepitant with, for example, Lomitapide, Pimozide, Avapritinib. The full list is on the Aprepitant page.

Full monographs, dosing and an interaction checker in the MediHelp app

Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.

Browse A–Z · Drug interactions

Get the app Sign in